Page last updated: 2024-12-07

a 82846a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID122131
CHEMBL ID411769
MeSH IDM0152173

Synonyms (8)

Synonym
110865-90-2
eremomycin
a 82846a
CHEMBL411769
a82846a
8-82846b
AKOS015969708
gtpl10959

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LD50 of eremomycin on its intravenous administration to albino mice amounted to 1760 (1460-2130) mg/kg."( [Preclinical toxicological study of the new antibiotic eremomycin. Its acute toxicity for laboratory animals].
Gol'dberg, LE; Shepelevtseva, NG; Shevniuk, LA; Stepanova, ES; Vertogradova, TP, 1987
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" Activity of eremomycin alone or in combination with tobramycin was studied with using 25 clinical strains of staphylococci."( [Study of the activity of a new glycopeptide antibiotic eremomycin combined with tobramycin against Staphylococci in vitro].
Iakushkina, IV; Malkova, IV; Prozorova, IN, 1988
)
0.27

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of eremomycin and teichoplanin after their extravascular administration was the same and amounted to 94 per cent."( [Glycopeptide antibiotics: eremomycin, vancomycin, and teicoplanin. Comparison of several parameters of pharmacokinetics and antimicrobial activity].
Filippos'iants, ST; Gol'dberg, LE; Malkova, IV, 1989
)
0.28
" Absolute bioavailability after subcutaneous administration averaged to 85 per cent."( [Pharmacokinetic study of eremomycin in an experiment].
Filippos'iants, ST; Malkova, IV, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID44140Minimal inhibitory concentration required to cause a microscopic detectable alteration of C3H/3T3 embryo murine fibroblast cell morphology2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID105655Inhibitory concentration of compound against proliferation of human T-lymphocytic cells MOLT-4/C8 was determined2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID206213Antibacterial activity against Staphylococcus epidermis 533 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID82110Effective concentration of compound required to protect human T-lymphocytic cells against the cytopathogenicity of HIV-12003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID207011Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3798 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID207010Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3797 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID68068Antibacterial activity against glycopeptide resistant Enterococcus faecium 569 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID47433Inhibitory concentration against proliferation of human T-lymphocytic (CEM) cells2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID66902Antibacterial activity against glycopeptide resistant Enterococcus faecalis 560 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID98356Inhibitory concentration of compound against proliferation of murine lukemia cells L1210 was determined2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID209587Antibacterial activity against Streptococcus haemolyticus 602 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID66903Antibacterial activity against glycopeptide susceptible Enterococcus faecalis 559 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID106723Effective concentration of compound required to protect C3H/3T3 embryo murine fibroblasts against the MSV induced transformation2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID83111Concentration required to protect human T-lymphocytic cells against the cytopathogenicity of HIV-22003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID68069Antibacterial activity against glycopeptide susceptible Enterococcus faecium 568 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (23.29)18.7374
1990's20 (27.40)18.2507
2000's27 (36.99)29.6817
2010's8 (10.96)24.3611
2020's1 (1.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.06 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other78 (98.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]